BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Healthtrust
McKinsey
UBS
Julphar
Boehringer Ingelheim
US Department of Justice
Chinese Patent Office
Baxter
Johnson and Johnson

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,220,767

« Back to Dashboard

Which drugs does patent 7,220,767 protect, and when does it expire?

Patent 7,220,767 protects ZOMIG and is included in one NDA.

Protection for ZOMIG has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
Summary for Patent: 7,220,767
Title:Pharmaceutical formulations containing zolmitriptan
Abstract:A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
Inventor(s): Dearn; Alan Roy (Hertfordshire, GB), Williamson; Sarah Louise (Hertfordshire, GB), Summers; John Simon (Hertfordshire, GB), Coomber; Trevor John (Hertfordshire, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/854,959
Patent Claim Types:
see list of patent claims
Composition; Formulation; Device;

Drugs Protected by US Patent 7,220,767

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca ZOMIG zolmitriptan SPRAY;NASAL 021450-003 Sep 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca ZOMIG zolmitriptan SPRAY;NASAL 021450-004 Sep 30, 2003 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,220,767

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9928578.5Dec 03, 1999

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Julphar
Queensland Health
Deloitte
Fish and Richardson
Chubb
US Department of Justice
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot